How Early Is Early Multiple Sclerosis?

Area of Science:

• Neuroimmunology
• Neurology
• Biomarker Discovery

Background:

• Optimizing diagnostic criteria for multiple sclerosis (MS) is key for early and accurate diagnosis.
• Early MS treatment is linked to slower disease progression and better long-term outcomes.
• Neuroinflammatory and neurodegenerative processes may precede symptom onset in MS.

Purpose of the Study:

• To review current research on MS pathology and potential biomarkers for early detection.
• To identify individuals with radiologically isolated syndrome (RIS) at high risk of progressing to MS.
• To increase clinician awareness of subclinical MS and emerging biomarkers for future clinical use.

Main Methods:

• Comprehensive literature review of studies on MS pathology.
• Analysis of research on laboratory and neuroimaging biomarkers for MS risk stratification.
• Focus on biomarkers for identifying individuals with RIS who may convert to definite MS.

Main Results:

• Neuroinflammatory and neurodegenerative processes can occur before MS symptoms manifest.
• A significant portion of individuals with RIS eventually develop MS.
• Currently, no approved treatments exist for RIS, highlighting the need for early detection biomarkers.

Conclusions:

• Accurate biomarkers are essential for identifying individuals with RIS who will progress to MS.
• Early detection of subclinical MS through biomarkers could enable timely intervention.
• Further research and validation of biomarkers are needed for clinical application in managing RIS.